nach oben

Targeted Oncology

Erschienen in:

01.12.2011 | Review

Hypomagnesaemia and targeted anti-epidermal growth factor receptor (EGFR) agents

verfasst von: Andreia Costa, Sabine Tejpar, Hans Prenen, Eric Van Cutsem

Erschienen in: Targeted Oncology | Ausgabe 4/2011

Einloggen, um Zugang zu erhalten

Abstract

Currently, targeted anti-epidermal growth factor receptor (EGFR) agents have an important role in the treatment of various cancers. These drugs, particularly anti-EGFR monoclonal antibodies, may induce electrolyte disorders, such as hypomagnesaemia and hypocalcaemia. Early symptoms of magnesium deficiency can easily go unrecognized. However, hypomagnesaemia can in rare cases lead to serious clinical manifestations, including cardiac arrhythmias or convulsions. The elective tubular expression of renal EGF/EGFR explains the mechanism of this class-related drug side effect. Inhibition of the EGFR induces a mutated-like transient receptor potential cation channel, subfamily M, member 6 (TRPM6) syndrome, characterized by urinary magnesium and calcium wasting. The risk of hypomagnesaemia is associated with treatment duration. It is a reversible toxicity; the recovery of magnesium serum levels is usually seen 4–6 weeks of stopping the anti-EGFR antibody. Using literature from peer-reviewed journals, this review reports the clinical trials findings and discusses the mechanisms and the treatment of hypomagnesaemia induced by anti-EGFR targeted agents.

Vivancoa I, Mellinghoff K (2010) Epidermal growth factor receptor inhibitors in oncology. Curr Op Oncol 22:573–578CrossRef

Izzedine H, Bahleda R, Khayat D et al (2010) Electrolyte disorders related to EGFR-targeting drugs. Crit Rev Oncol Hematol 73:213–219PubMedCrossRef

Capdevila J, Elez E, Macarulla T, Ramos FJ, Ruiz-Echari M, Tabernero J (2009) Anti-epidermal growth factor receptor monoclonal antibodies in cancer treatment. Cancer Treat Rev 35:354–363PubMedCrossRef

Dai LJ, Ritchie G, Kerstan D, Kang HS, Cole DE, Quamme GA (2001) Magnesium transport in the renal distal convoluted tubule. Physiol Rev 81:51–84PubMed

Romani AM, Scarpa A (2000) Regulation of cellular magnesium. Front Bioscien 5:720–734CrossRef

Ferment O, Garnier PE, Touitou Y (1987) Comparison of the feedback effect of magnesium and calcium on parathyroid hormone secretion in man. J Endocrinol 113:117–122PubMedCrossRef

Cholst IN, Steinberg SF, Tropper PJ, Fox HE, Segre GV, Bilezikian JP (1984) The influence of hypomagnesaemia on serum calcium and parathyroid hormone levels in human subjects. N Engl J Med 310:1221–1225PubMedCrossRef

Konrad M, Schlingmann KP, Gudermann T (2004) Insights into the molecular nature of magnesium homeostasis. Am J Physiol Renal Physiol 286:599–605CrossRef

Saif MW (2008) Management of Hypomagnesemia in cancer patients receiving chemotherapy. J Support Oncol 6:243–248PubMed

10.

Agus ZS (1999) Hypomagnesemia. J Am Soc Nephrol 10:1616–1622PubMed

11.

Schrag D, Chung KY, Flombaum C, Saltz L (2005) Cetuximab therapy and symptomatic hypomagnesemia. J Natl Cancer Inst 97:1221–1224PubMedCrossRef

12.

Fakih MG, Wilding G, Lombardo J (2006) Cetuximab-induced hypomagnesemia in patients with colorectal cancer. Clin Colorectal Cancer 6:152–156PubMedCrossRef

13.

Erbitux package insert. March 2006. ImClone Systems Incorporated, New York, NY 10014, USA, and Bristol-Myers Squibb Company, Princeton, NY 08543, USA

14.

Tejpar S, Piessevaux H, Claes K et al (2007) Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study. Lancet Oncol 8:387–394PubMedCrossRef

15.

Liu L, Cao Y, Tan A, Liao C, Gao F (2009) Cetuximab-based therapy versus non-cetuximab therapy for advanced cancer: a meta-analysis of 17 randomized controlled trials. Cancer Chemother Pharmacol 65:849–861PubMedCrossRef

16.

Jonker DJ, O’Callaghan CJ, Karapetis CS et al (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357:2040–2048PubMedCrossRef

17.

Sobrero AF, Maurel J, Fehrenbacher L et al (2008) EPIC: phase III trial of cetuximab plus irinotecan after Fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 26:2311–2319PubMedCrossRef

18.

Tol J, Koopman M, Rodenburg CJ et al (2008) A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity. Ann Oncol 19:734–738PubMedCrossRef

19.

Butts CA, Bodkin D, Middleman EL et al (2007) Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer. J Clin Oncol 25(36):5777–5784, Erratum in: J Clin Oncol (2008) 26:3295PubMedCrossRef

20.

Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA, Eastern Cooperative Oncology Group (2005) Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 23(34):8646–8654, Erratum in: J Clin Oncol (2006) 24:724PubMedCrossRef

21.

Vermorken JB, Mesia R, Rivera F et al (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359:1116–1127PubMedCrossRef

22.

Vincenzi B, Santini D, Galluzzo S et al (2008) Patients treated with cetuximab plus irinotecan as early magnesium reduction in advanced colorectal predictive factor of efficacy and outcome. Clin Cancer Res 14:4219–4224PubMedCrossRef

23.

Vincenzi B, Galluzzo S, Santini D et al (2011) Early magnesium modifications as a surrogate marker of efficacy of cetuximab-based anticancer treatment in KRAS wild-type advanced colorectal cancer patients. Ann Oncol 22:1141–1146. doi:10.1093/annonc/mdq550 PubMedCrossRef

24.

Vickers MM, Karapetis CS, Tu D et al (2011) The influence of hypomagnesemia (hMg) on overall survival (OS) in phase III randomized study of cetuximab (CET) plus best supportive care (BSC) versus BSC: NCIC CTG/AGITG CO. 17. J Clin Oncology 29(suppl):abstr. 3601

25.

Fakih MG (2008) Management of Anti-EGFR–Targeting Monoclonal Antibody–Induced Hypomagnesemia. Oncology. Vol. 22 No. 1. http://www.cancernetwork.com/display/article/10165/1147011 1

26.

Van Cutsem E, Peeters M, Siena S et al (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25:1658–1664PubMedCrossRef

27.

Hecht JR, Mitchell E, Chidiac T et al (2008) A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 27:672–680PubMedCrossRef

28.

Dimke H, van der Wijst J, Alexander TR et al (2010) Effects of the EGFR inhibitor erlotinib on magnesium handling. J Am Soc Nephrol 21:1309–1316PubMedCrossRef

29.

Hoenderop JG, Bindels RJ (2005) Epithelial Ca2+ and Mg2+ channels in health and disease. J Am Soc Nephrol 16:15–26PubMedCrossRef

30.

Quamme GA (1997) Renal magnesium handling: new insights in understanding old problems. Kidney Int 52:1180–1195PubMedCrossRef

31.

Voets T, Nilius B, Hoefs S et al (2004) TRPM6 forms the Mg2+ influx channel involved in intestinal and renal Mg2+ absorption. J Biol Chem 279:19–25PubMedCrossRef

32.

Simon DB, Lu Y, Choate KA et al (1999) Paracellin-1, a renal tight junction protein required for paracellular Mg2+ resorption. Science 285(5424):103–106PubMedCrossRef

33.

Schlingmann KP, Weber S, Peters M et al (2002) Hypomagnesemia with secondary hypocalcemia is caused by mutations in TRPM6, a new member of the TRPM gene family. Nat Genet 31:166–170PubMedCrossRef

34.

Walder RY, Landau D, Meyer P et al (2002) Mutation of TRPM6 causes familial hypomagnesemia with secondary hypocalcemia. Nat Genet 31:171–174PubMedCrossRef

35.

Müller D, Kausalya PJ, Meij IC, Hunziker W (2006) Familial hypomagnesemia with hypercalciuria and nephrocalcinosis: blocking endocytosis restores surface expression of a novel claudin-16 mutant that lacks the entire C-terminal cytosolic tail. Hum Mol Genet 15:1049–1058PubMedCrossRef

36.

Konrad M, Schaller A, Seelow D et al (2006) Mutations in the tight-junction gene claudin 19 (CLDN19) are associated with renal magnesium wasting, renal failure, and severe ocular involvement. Am J Hum Genet 79:949–957PubMedCrossRef

37.

Groenestege WM, Thébault S, van der Wijst J et al (2007) Impaired basolateral sorting of pro-EGF causes isolated recessive renal hypomagnesemia. J Clin Invest 117:2260–2267PubMedCrossRef

38.

Salido EC, Barajas L, Lechago J, Laborde NP, Fisher DA (1986) Immunocytochemical localization of epidermal growth factor in mouse kidney. J Histochem Cytochem 34:1155–1160PubMedCrossRef

39.

Gesualdo L, Di Paolo S, Calabró A et al (1996) Expression of epidermal growth factor and its receptor in normal and diseased human kidney: an immunohistochemical and in situ hybridization study. Kidney Int 49:656–665PubMedCrossRef

40.

Rall LB, Scott J, Bell GI et al (1985) Mouse prepro-epidermal growth factor synthesis by the kidney and other tissues. Nature 313:228–231PubMedCrossRef

41.

Bell GI, Fong NM, Stempien MM et al (1986) Human epidermal growth factor precursor: cDNA sequence, expression in vitro and gene organization. Nucl Acids Res 14:8427–8446PubMedCrossRef

Titel: Hypomagnesaemia and targeted anti-epidermal growth factor receptor (EGFR) agents
verfasst von: Andreia Costa
Sabine Tejpar
Hans Prenen
Eric Van Cutsem
Publikationsdatum: 01.12.2011
Verlag: Springer-Verlag
Erschienen in: Targeted Oncology / Ausgabe 4/2011
Print ISSN: 1776-2596
Elektronische ISSN: 1776-260X
DOI: https://doi.org/10.1007/s11523-011-0200-y

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Hypomagnesaemia and targeted anti-epidermal growth factor receptor (EGFR) agents

Abstract

Neu im Fachgebiet Onkologie

Darf man die Behandlung eines Neonazis ablehnen?

Erhöhte Mortalität bei postpartalem Brustkrebs

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

Update Onkologie

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2011

The carriages to the good drivers

Hematologic toxicities of small molecule tyrosine kinase inhibitors

Pulmonary toxicities from targeted therapies: a review

Heart to heart with trastuzumab: a review on cardiac toxicity

Posterior reversible encephalopathy syndrome induced by anti-VEGF agents

Cardiovascular toxicity of anti-angiogenic drugs

Neu im Fachgebiet Onkologie

Darf man die Behandlung eines Neonazis ablehnen?

Erhöhte Mortalität bei postpartalem Brustkrebs

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

Update Onkologie